Potential mechanisms of resistance to cytarabine in AML patients.
Leuk Res
; 26(7): 621-9, 2002 Jul.
Article
em En
| MEDLINE
| ID: mdl-12008078
ABSTRACT
To determine whether the human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), cytoplasmic 5'-nucleotidase (5NT), cytidine deaminase (CDD), topoisomerase I (TOPO I) and topoisomerase II alpha (TOPO II) are involved in clinical resistance to cytarabine (ara-C), we analyzed the level of expression of these parameters by reverse transcriptase polymerase chain reaction (rt-PCR), at diagnosis in the blast cells of 77 acute myeloid leukemia (AML) patients treated with ara-C, including 31 for whom samples were collected at first relapse. By univariate and/or multivariate analyses, patients with expression of 5NT or hENT1 deficiency at diagnosis had significantly shorter disease-free survival (DFS) and overall survival (OS). These results suggest that expression of 5NT and reduced hENT1 in leukemic blasts at diagnosis are correlated with clinical outcome and may play a role in resistance mechanisms to ara-C in patients with AML.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mieloide
/
Resistencia a Medicamentos Antineoplásicos
/
Citarabina
/
Proteínas de Neoplasias
/
Antimetabólitos Antineoplásicos
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
País/Região como assunto:
Europa
Idioma:
En
Ano de publicação:
2002
Tipo de documento:
Article